{"name":"Neuraly, Inc.","slug":"neuraly-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxOTWRKUFFxSkZqdnVqMGlXaEVwaWtLV0dJc21RU2tqeGZpSzhhbEplcWFNUG8zVlk4OE9UVW56VmY0NmJkYjJTTTE0M3oxNlhteE1pNk1IQXhzZzVmTTZYNkVFR2tXMmlDdl84c1c5RHBSQU4wTDFhNzlCVDY5SldIcTBreHg0NnlRR0E0Q0hNM2xMRU43bXMwS0lkbGRKSzhHY2pWVkw2T29zd2w5TEItSW1uQjE5ejVOcmdZNWRQOTZfeFZyUEZucG9jZlZUMk9DMkhacVVPVngyU19ia04tUV9KZTZjM2duUldRN1Yzb2NraTB3VW5mbm9odEpJSEZxS2NvOWlZLThzaTRaWF9uZE9IRmVXd0d2YXVmRUhIOEtIaVItOVJzSGF6M0hDY3dENVhDODQzMzZ6U1BkWWlOdDM5Q2U?oc=5","date":"2026-04-08","type":"pipeline","source":"Barchart.com","summary":"Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma AstraZeneca, Eccogene, Pfizer, Sciwind Biosciences USA Co., Ltd., MediciNova - Barcha","headline":"Diabetes Market: Rapid Increment Driven by Innovation by 2032 – DelveInsight | Eli Lilly and Company, Regor Pharma Astra","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAJBVV95cUxOVXMzZHVmelBCazRfQThzdU5GLUxpaDlzX2l4QV9keHZXZjg5LVVzRExPMHpmWi1LYWtya2JxUEY2ZnpNSnJaZGI2VUpLZlpLY296U0ZxX2ltRl9RZlpTbWloQ0MtUExQU0pUVFk3QWJ5NVZ0aGUxVU9TdUNtMXVvdmtfNXVYNWQxRkVDbnpmc3Fmd25KSklHbDE2dUhkSXdoLUZHOWRzMkFreTdVRW56ZWZtcG05UU9ZWVZXUmNxNjBNR1ZCUURvSzRCRS1BMm5NYXMwT2ZicUJReE5zNWdmZ1hqcHc5YnJXQkFTYVNZYUlqN0hhdEs0UlkyaWxncUVpSTVHaFEwUFhkVUN6dlZ1b0RkY2VlNHRrbW44ODZGVjhiME8xTm1PR2ZUdU5qb1NyMUpjZnRsUGNia3Nt?oc=5","date":"2025-06-16","type":"trial","source":"Business Wire","summary":"D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Improvements in Liver and Metabolic Health - Business Wire","headline":"D&D Pharmatech Announces Positive Phase 2 Results for DD01 in MASH with Robust Reductions in Liver Fat Accompanied by Im","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxQdzNUZFRCTVhoSUllbW1XakkxWEZseVhpUVpUMldwNkhMSGZSR0EtYlFZdTREMG5hVUpPWDRwMEJfNW94eU1JbzdXeUVubkl5MnZtUFZLWTMzME9kbW9yTnFkVWdtQjJLRjVBdWtxeHMyTDh6Rk5peXNDaHUxSWthampFTVdfbVowNExVUmFvMnpOYjlsVGs1MmpLbHlvbW56RmlBOE5zVnZzY2VVYnlrU2dST0k5RmVGTU9GdVI5eDBDd1lURE1vU2tBV1ZuR1lwUzNwanBWS29uNW5qZVVaVGtvT1VkdXVkU2swQlQxQVgtNWVkdk95UEVJUVRycDAzNk9mSjl0b1RZaXV1cGxzSlg1bUE3Q3FTWmVLVFgzWW9YQ2M5amNaeQ?oc=5","date":"2025-02-13","type":"trial","source":"GlobeNewswire","summary":"Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel - GlobeNewswire","headline":"Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-02-03","type":"trial","source":"Business Wire","summary":"D&D Pharmatech Announces Completion of Patient Enrollment for a 48-Week Phase 2 Trial Evaluating the Effectiveness of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist, in the Treatment of MAS","headline":"D&D Pharmatech Announces Completion of Patient Enrollment for a 48-Week Phase 2 Trial Evaluating the Effectiveness of DD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_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?oc=5","date":"2024-08-21","type":"trial","source":"Business Wire","summary":"D&D Pharmatech Announces Initiation of Dosing in a Phase 2 Trial Designed to Evaluate the Efficacy and Safety of DD01, a Long-Acting, Dual GLP-1/Glucagon Receptor Agonist in Overweight/Obese Subjects ","headline":"D&D Pharmatech Announces Initiation of Dosing in a Phase 2 Trial Designed to Evaluate the Efficacy and Safety of DD01, a","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxNS1BvcG9lZHNrbUlfd1RJVWtuRjZkWDcyWnk5MnRwVXUybWpOZTBiYnI0WXdObUR2MElLS1BqUkNfS0RZcGJwWXQtWGxVTDY4ZVJoSF9WR2h4dmdqUVBhak43a2U0N1RZWXVaNEZ2OVllWnlydS1NeEhTcV9VNEQ0YUR1aTMzWDV3RVNmb2U5Y2gyWW01SFlveDN6QVhQclZkU0VCOTJWS3IyLWNucEM2MXEzeW5ZekMtOXE5SkV4Vk5uT3JmTms2T21INklWQnRTVDFkRmFCSTlteG5QZHZ4dTRaZ0diWDA?oc=5","date":"2024-04-02","type":"regulatory","source":"Business Wire","summary":"D&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH/MASH - Business Wire","headline":"D&D Pharmatech Granted Fast Track Designation from US FDA for DD01 for the Treatment of NASH/MASH","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQTG9KSkZTY1FUVlFyY2hIVU1XNnRubG5iVE5uWkxndEQ2TnRZNm1wdkdYMk1aWVpGaUE3VGVtcElPOEJfbjRGWl9ZMUEtVENUMGZqekprNWJ4SjV4VFdmdk5NRDVRSkxmWWxUOFFoQThZOHJidHZDZFpDbk9qVm1QQXRyUjNiYVRoT0hEV0JyLS1nZFhWTUZhMl9ycmpaMFBpVzlvV2Zn?oc=5","date":"2023-03-27","type":"trial","source":"Fierce Biotech","summary":"Neuraly points to younger patients for hope as Parkinson's bet fails phase 2 - Fierce Biotech","headline":"Neuraly points to younger patients for hope as Parkinson's bet fails phase 2","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxQTW9Zc2Y4LTRLaE5CeEZxQWlrUmJLMVBuMEtfWjc2OUlSaUJHbjBJQVNVbTBWdUZWREpvTno2M3FYM0NGR2d1X0NpWVlOMDdHLVN5ejhibXdic3MxWmZZbFFYaERtZmdZSHFxdWw0VDhUMTNmcmJLZTAwaU9GNlFrcG1pRjVIZ2ZSZ1N6OFFEckd6RWlZTWtLRzEwV1pBSFU3dlk5cGFxNGtxYUZXWEM1YzBWdDVuNXJwRWc4clE4bVdOR3VpMkticFFobXkyLW9TMEtKWFhibjF3WWxtQ3hVTGwzbHZoNlVxbzZQZVJSSFlmRE1VcGNZa0JjOA?oc=5","date":"2021-09-27","type":"pipeline","source":"Business Wire","summary":"D&D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China - Business Wire","headline":"D&D Pharmatech Announces Agreement with Salubris Pharmaceuticals for Licensing and Development of DD01 in China","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBJeC1wbDl3QUdvLUZfM0NiOVAxakJUa19nQzhJVnVPOUVLSU0yaG1BcTZkVVFYZ0lyT0JwLTdENi1Lczd0T0dvWFlsMWE3MW9fRE1NNFJhRnZ1RmxqNlhEX0VuN0RaM09sNUNmMXVDUV94M3UwUjNLNUN1UHNTQQ?oc=5","date":"2019-08-14","type":"trial","source":"BioSpace","summary":"D&D Pharmatech's $137.1 Million Series B to Support Clinical Trials in Alzheimer's, Parkinson's and Fibrosis - BioSpace","headline":"D&D Pharmatech's $137.1 Million Series B to Support Clinical Trials in Alzheimer's, Parkinson's and Fibrosis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxPUTdKUDA2MzlBWi1QeEV6MklhVk9hX3FyNmxKa2ZBc3E0cmxzVGhqdGZZWV8yY0g5Z05nOEl2Rk5GQ0s0TlZ3a25wX2d2cmt6d3hHa29QUjF1YVhEcDNLSFpmV3hDamdTaFBRcTMtU0pmeFUyekpKQUZJeTBsYXBJTnZidUtfaEt5SE9XbWxRUTRvQm9lMzBLTmVoM1V0dmdfbGlSdnoxRmNwQWNCWFhpVmlR?oc=5","date":"2018-07-18","type":"trial","source":"Fierce Biotech","summary":"Johns Hopkins startup Neuraly plans phase 1 Parkinson’s trial with $36M round - Fierce Biotech","headline":"Johns Hopkins startup Neuraly plans phase 1 Parkinson’s trial with $36M round","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxPWXpONEVIOER2cGQxQTFLY0ZkdWI2M3pwQUo3S2xBMTdENklVUTluSE5wTVRLMnNLRFR6UEhSZTlHb1VlM0Z6dW1KOEVZN1pMTDRad3EzTkszcWF1dGNZZmZsUjI3b2dybTJxWjdCcmpPcndJTVM1aXhYc1lKd0d4VU5kRXgwbTZIalNJc3ZydElvUWl1b044bkhtODRpZGg4a0E?oc=5","date":"2018-07-18","type":"pipeline","source":"BioSpace","summary":"Startup Neuraly Launches with $36 Million: Targets Neurodegenerative Diseases - BioSpace","headline":"Startup Neuraly Launches with $36 Million: Targets Neurodegenerative Diseases","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":8,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}